Femtogenix presents data on antibody drug conjugates containing reduced potency payloads in solid tumour models

This article was originally published here

The data is being presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston,USA. Within its PDD platform, Femtogenix has developed a lower potency DNA mono-alkylator

The post Femtogenix presents data on antibody drug conjugates containing reduced potency payloads in solid tumour models appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply